155 related articles for article (PubMed ID: 1963909)
21. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
[TBL] [Abstract][Full Text] [Related]
22. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects.
Kawamura M; Imanashi M; Matsushima Y; Ito K; Hiramori K
Clin Exp Pharmacol Physiol; 1992 Aug; 19(8):547-53. PubMed ID: 1326422
[TBL] [Abstract][Full Text] [Related]
23. Kinetics and dynamics of enalapril in patients with liver cirrhosis.
Ohnishi A; Tsuboi Y; Ishizaki T; Kubota K; Ohno T; Yoshida H; Kanezaki A; Tanaka T
Clin Pharmacol Ther; 1989 Jun; 45(6):657-65. PubMed ID: 2543535
[TBL] [Abstract][Full Text] [Related]
24. [Angiotensin converting enzyme inhibitory activity of MK-0521 in vivo and antihypertensive effect of its single oral administration on blood pressure and effect on the renin-angiotensin system in 2-kidney Goldblatt hypertensive dogs].
Oda M; Ino Y; Suzuki K; Sato T; Iwamoto S; Iwaki M
Nihon Yakurigaku Zasshi; 1989 Apr; 93(4):225-34. PubMed ID: 2545579
[TBL] [Abstract][Full Text] [Related]
25. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
Ferrario CM; Jessup J; Chappell MC; Averill DB; Brosnihan KB; Tallant EA; Diz DI; Gallagher PE
Circulation; 2005 May; 111(20):2605-10. PubMed ID: 15897343
[TBL] [Abstract][Full Text] [Related]
26. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
Erman A; Boner G; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
[TBL] [Abstract][Full Text] [Related]
27. Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.
Reams GP; Lal SM; Whalen JJ; Bauer JH
J Clin Hypertens; 1986 Sep; 2(3):245-53. PubMed ID: 3023555
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
[TBL] [Abstract][Full Text] [Related]
29. Blockade of angiotensin converting enzyme in circumventricular organs of the brain after oral lisinopril administration demonstrated by quantitative in vitro autoradiography.
Sakaguchi K; Chai SY; Jackson B; Johnston CI; Mendelsohn FA
Clin Exp Pharmacol Physiol; 1987 Mar; 14(3):155-8. PubMed ID: 2822304
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition.
Heeg JE; de Jong PE; van der Hem GK; de Zeeuw D
Kidney Int; 1991 Oct; 40(4):734-41. PubMed ID: 1660550
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of angiotensin converting enzyme from sheep tissues by captopril, lisinopril and enalapril.
Udupa EG; Rao NM
Indian J Biochem Biophys; 1997 Dec; 34(6):524-8. PubMed ID: 9594434
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin converting enzyme inhibition in plasma and tissues.
Johnston CI; Cubela R; Sakaguchi K; Jackson B
Clin Exp Hypertens A; 1987; 9(2-3):307-21. PubMed ID: 3038391
[TBL] [Abstract][Full Text] [Related]
33. Radioimmunoassay for the quantitation of lisinopril and enalaprilat.
Worland PJ; Jarrott B
J Pharm Sci; 1986 May; 75(5):512-6. PubMed ID: 3016233
[TBL] [Abstract][Full Text] [Related]
34. Short term effects of acute inhibition of the angiotensin-converting enzyme on the renin-angiotensin system and plasma atrial natriuretic peptide in healthy dogs fed a low-sodium diet versus a normal-sodium diet.
Koch J; Pedersen HD; Jensen AL; Flagstad A; Poulsen K; Bie P
Zentralbl Veterinarmed A; 1994 Mar; 41(2):121-7. PubMed ID: 8091887
[TBL] [Abstract][Full Text] [Related]
35. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man.
Semple PF; Cumming AM; Meredith PA; Morton JJ
Cardiovasc Drugs Ther; 1987; 1(1):45-50. PubMed ID: 2856460
[TBL] [Abstract][Full Text] [Related]
36. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
37. Altered angiotensin-converting enzyme in lung and extrapulmonary tissues of hypoxia-adapted rats.
Oparil S; Narkates AJ; Jackson RM; Ann HS
J Appl Physiol (1985); 1988 Jul; 65(1):218-27. PubMed ID: 2841276
[TBL] [Abstract][Full Text] [Related]
38. Protection of the arterial internal elastic lamina by inhibition of the renin-angiotensin system in the rat.
Huang W; Alhenc Gelas F; Osborne-Pellegrin MJ
Circ Res; 1998 May; 82(8):879-90. PubMed ID: 9576107
[TBL] [Abstract][Full Text] [Related]
39. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition.
Keuneke C; Yacullo R; Metzger R; Hellmann T; Peters J; Ganten D
Eur Heart J; 1990 May; 11 Suppl D():11-6. PubMed ID: 2163328
[TBL] [Abstract][Full Text] [Related]
40. Lisinopril in hypertensive patients with and without renal failure.
van Schaik BA; Geyskes GG; Boer P
Eur J Clin Pharmacol; 1987; 32(1):11-6. PubMed ID: 3034622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
